Solid IO

Patient-specific tumour-on-chip: reproduces the tumour microenvironment and shows in real time how an individual cancer responds to immunotherapies and combinations, so the therapy can be chosen before the patient is treated. University of Helsinki spin-out, legal name Solid Immuno-Oncology Oy; founders Heidi Haikala (CSO), Noora Hujala (CEO) and Bassel Alsaed.

The row

Sector

Therapeutics & Diagnostics

Stage

Pre-revenue — No sales yet

Location

Helsinki

Founded

2025

Research origin

Univ. of Helsinki

Business ID

3500055-3 · Finnish trade register

Funding

€0.8M (2/2025; Nordic Science Investments, BSV Ventures, University of Helsinki Funds, angel investor)

Links

Where this sits on the map

Solid IO is one of 33 companies in Therapeutics & Diagnostics. The others:

How this row was decided

Every row on this map is checked by hand against the trade register and the company's own material, and placed in the sector that best describes its business or its technology. Service firms and consultancies are left out, however advanced the technology they work with — the test is where the revenue comes from. Only funding figures the company or its investor has published are shown. The full rules are on the landscape ↗